NO20021394L - Quetiapingranuler - Google Patents

Quetiapingranuler

Info

Publication number
NO20021394L
NO20021394L NO20021394A NO20021394A NO20021394L NO 20021394 L NO20021394 L NO 20021394L NO 20021394 A NO20021394 A NO 20021394A NO 20021394 A NO20021394 A NO 20021394A NO 20021394 L NO20021394 L NO 20021394L
Authority
NO
Norway
Prior art keywords
quetiapingranuler
Prior art date
Application number
NO20021394A
Other languages
English (en)
Other versions
NO320908B1 (no
NO20021394D0 (no
Inventor
Daniel Boyd Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021394(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20021394D0 publication Critical patent/NO20021394D0/no
Publication of NO20021394L publication Critical patent/NO20021394L/no
Publication of NO320908B1 publication Critical patent/NO320908B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NO20021394A 1999-09-21 2002-03-20 Granulformulering, fremgangsmate til fremstilling derav, anvendelse derav for behandling av sykdommer, samt pose som inneholder formuleringen. NO320908B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922271.3A GB9922271D0 (en) 1999-09-21 1999-09-21 Formulation
PCT/GB2000/003598 WO2001021179A1 (en) 1999-09-21 2000-09-18 Quetiapine granules

Publications (3)

Publication Number Publication Date
NO20021394D0 NO20021394D0 (no) 2002-03-20
NO20021394L true NO20021394L (no) 2002-03-20
NO320908B1 NO320908B1 (no) 2006-02-13

Family

ID=10861288

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021394A NO320908B1 (no) 1999-09-21 2002-03-20 Granulformulering, fremgangsmate til fremstilling derav, anvendelse derav for behandling av sykdommer, samt pose som inneholder formuleringen.

Country Status (37)

Country Link
US (3) US6599897B1 (no)
EP (1) EP1218009B1 (no)
JP (1) JP2003509461A (no)
KR (1) KR100748823B1 (no)
CN (3) CN1331472C (no)
AR (1) AR032596A1 (no)
AT (1) ATE288272T1 (no)
AU (1) AU776292B2 (no)
BG (1) BG65469B1 (no)
BR (1) BR0014107A (no)
CA (1) CA2383131A1 (no)
CO (1) CO5180585A1 (no)
CZ (1) CZ301585B6 (no)
DE (1) DE60017923T2 (no)
DK (1) DK1218009T3 (no)
EE (1) EE200200150A (no)
EG (1) EG24226A (no)
ES (1) ES2235941T3 (no)
GB (2) GB9922271D0 (no)
HK (1) HK1047706B (no)
HU (1) HUP0203531A3 (no)
IL (2) IL148440A0 (no)
IS (1) IS2139B (no)
MX (1) MXPA02002627A (no)
MY (1) MY130208A (no)
NO (1) NO320908B1 (no)
NZ (1) NZ517549A (no)
PL (1) PL198824B1 (no)
PT (1) PT1218009E (no)
RU (1) RU2256453C2 (no)
SI (1) SI1218009T1 (no)
SK (1) SK286884B6 (no)
TR (1) TR200200716T2 (no)
TW (1) TWI226832B (no)
UA (1) UA73529C2 (no)
WO (1) WO2001021179A1 (no)
ZA (1) ZA200201709B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
WO2003039516A1 (en) * 2001-11-07 2003-05-15 Fujisawa Pharmaceuticla Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
JP4514473B2 (ja) * 2004-02-23 2010-07-28 富士通株式会社 コンピュータシステム、中央装置及びプログラム実行方法
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
EP1879874A2 (en) * 2005-04-21 2008-01-23 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
WO2007086079A2 (en) 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
EP2357174A1 (en) * 2006-05-09 2011-08-17 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
CA2657202A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S.A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
AR062860A1 (es) * 2006-09-15 2008-12-10 Astrazeneca Ab Combinaciones terapeuticas 482
WO2008052354A1 (en) * 2006-11-03 2008-05-08 University Of Saskatchewan Method of treating demyelination diseases
WO2008091592A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
ATE480227T1 (de) * 2007-02-14 2010-09-15 Lesvi Laboratorios Sl Pharmazeutische zusammensetzungen mit quetiapinfumarat
RU2492695C2 (ru) * 2008-02-27 2013-09-20 КРАФТ ФУДЗ ГЛОБАЛ БРЭНДЗ ЭлЭлСи Многозональное кондитерское изделие
SI2262486T1 (sl) 2008-08-01 2013-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Sestavek kvetiapina
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
EP2987789A1 (en) 2009-12-31 2016-02-24 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
PT2544536T (pt) 2010-03-11 2019-01-23 Kempharm Inc Conjugados de ácido gordo e quetiapina, processo de preparação e utilização do destes
SG185497A1 (en) 2010-05-20 2012-12-28 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
EP0416773B1 (en) * 1989-08-31 1993-03-03 Takeda Chemical Industries, Ltd. Vitamin b12 composition
IT1250701B (it) * 1991-07-24 1995-04-21 Angelini Francesco Ist Ricerca Composizione farmaceutica solida per uso orale a base di dapiprazolo
JPH06100602A (ja) * 1992-09-18 1994-04-12 Asahi Chem Ind Co Ltd 経口固形製剤およびその製造方法
US5397576A (en) * 1992-09-23 1995-03-14 Hoffmann-La Roche Inc. Spray triturated micronutrient compositions
ZA973433B (en) * 1996-04-24 1997-12-10 Shionogi & Co A sertindole-containing preparation and a method for producing the same.
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
JP2001501207A (ja) * 1996-09-24 2001-01-30 イーライ・リリー・アンド・カンパニー コーティングされた粒子製剤
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation

Also Published As

Publication number Publication date
EP1218009B1 (en) 2005-02-02
MY130208A (en) 2007-06-29
CZ301585B6 (cs) 2010-04-21
KR100748823B1 (ko) 2007-08-13
GB0021406D0 (en) 2000-10-18
PT1218009E (pt) 2005-05-31
HK1047706B (zh) 2005-06-10
BR0014107A (pt) 2002-08-20
ATE288272T1 (de) 2005-02-15
PL198824B1 (pl) 2008-07-31
TR200200716T2 (tr) 2002-06-21
EG24226A (en) 2008-11-10
DE60017923T2 (de) 2006-01-12
PL357369A1 (en) 2004-07-26
AU7302300A (en) 2001-04-24
CN1626094A (zh) 2005-06-15
CN1331472C (zh) 2007-08-15
CZ2002974A3 (cs) 2002-06-12
US7022692B2 (en) 2006-04-04
CA2383131A1 (en) 2001-03-29
AR032596A1 (es) 2003-11-19
CO5180585A1 (es) 2002-07-30
DK1218009T3 (da) 2005-05-09
ES2235941T3 (es) 2005-07-16
US20040228914A1 (en) 2004-11-18
IL148440A0 (en) 2002-09-12
CN1899288A (zh) 2007-01-24
SK286884B6 (sk) 2009-07-06
NZ517549A (en) 2003-10-31
NO320908B1 (no) 2006-02-13
CN1188130C (zh) 2005-02-09
EE200200150A (et) 2003-04-15
HUP0203531A2 (hu) 2003-02-28
RU2256453C2 (ru) 2005-07-20
BG106509A (en) 2002-12-29
HUP0203531A3 (en) 2004-12-28
KR20020033186A (ko) 2002-05-04
BG65469B1 (bg) 2008-09-30
JP2003509461A (ja) 2003-03-11
IS2139B (is) 2006-08-15
US20060159768A1 (en) 2006-07-20
GB9922271D0 (en) 1999-11-17
ZA200201709B (en) 2003-05-28
SI1218009T1 (en) 2005-06-30
EP1218009A1 (en) 2002-07-03
SK3722002A3 (en) 2002-07-02
NO20021394D0 (no) 2002-03-20
IS6308A (is) 2002-03-19
IL148440A (en) 2007-07-04
TWI226832B (en) 2005-01-21
US6599897B1 (en) 2003-07-29
AU776292B2 (en) 2004-09-02
DE60017923D1 (de) 2005-03-10
MXPA02002627A (es) 2002-07-30
WO2001021179A1 (en) 2001-03-29
UA73529C2 (uk) 2005-08-15
CN1374867A (zh) 2002-10-16
HK1047706A1 (en) 2003-03-07

Similar Documents

Publication Publication Date Title
DE50010505D1 (de) Gurtaufrollersystem
DE122007000064I1 (de) Erythropoietinkonjugate
DE10084676T1 (de) Einmallanzettvorrichtung
DE50002834D1 (de) Handstempel
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
IS2139B (is) Kvetíapínagnir
DE50009570D1 (de) Wechselcorrugator
NO20022515L (no) Brönnpulsgiver
DE50000805D1 (de) Aufsitzspanner
DE50006899D1 (de) Antistatikum
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50003660D1 (de) Diacylhydrazinderivate
DE50012482D1 (de) Tibiamarknagel
DE50003259D1 (de) Textilie
DE50006013D1 (de) Anschlagpuffer
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
DE50006759D1 (de) Piperidinalkohole
DE50009208D1 (de) Hydroxyphenylvinylthiazole
DE50006829D1 (de) Benzoylpyridazine
DE10082008D2 (de) Ausbeulgerät
DE50015176D1 (de) Polschenkelträger
ATE440824T1 (de) Nitro-sulfobenzamide
DE50003283D1 (de) Exzenterspannzwinge

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees